Materias dentro de su búsqueda.
Mostrando 1,741 - 1,760 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.67s Limitar resultados
  1. 1741
    “…CONCLUSION: Antibody-conjugated nanoparticles were shown to discriminate between Her2(+) and Her2(−) cells, and thus have the potential to be used in active targeted drug delivery, with reduction of drug side effects in Her2(+) breast and ovarian cancers.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
  2. 1742
    “…Early recurrences higher in HER-2 positive (66.6% versus 35.4%, P = 0.048). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain
  3. 1743
    “…In contrast, FISH-negative USC was negative for Her2/neu ECD shedding. Serum Her2/neu ECD levels in patients harbouring 3+Her2/neu tumours were higher than those found in healthy women (P=0.02) or USC patients with 2+ or 1+/negative Her2/neu expression (P=0.02). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
  4. 1744
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviours
  5. 1745
    “…INTRODUCTION: Human epidermal growth factor receptor 2 (HER2)-amplified breast cancer represents a clinically well-defined subgroup due to availability of targeted treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
  6. 1746
    “…Fluorescence in situ hybridization (FISH) assay is considered the “gold standard” in evaluating HER2/neu (HER2) gene status. However, FISH detection is costly and time consuming. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization
  7. 1747
    “…The HER2-PI3K pathway is the one of the most mutated pathways in cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart
  8. 1748
    por Shipman, H, Clarke, A
    Publicado 2012
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    "It's not even about her it's about the whole family": accounts of participation in a family cancer study
  9. 1749
    “…Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 oncoprotein, can effectively target HER2-positive breast cancer through several mechanisms. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
  10. 1750
    “…In August 2006, the Australian government approved subsidized trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, and it was mandated that HER2 testing should be performed using in situ hybridization (ISH) rather than immunohistochemistry (IHC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
  11. 1751
    “…HER2 is a promising target for immunotherapeutic interventions with T cell-based approaches since it is amplified and overexpressed in 20–30% of breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
  12. 1752
    “…BACKGROUND: One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an epitope on subdomain IV of the extracellular domain of HER2 is used for therapy of HER2-overexpressing mammary tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
  13. 1753
    por Tang, Liyang
    Publicado 2012
    “…BACKGROUND: The patient’s anxiety before seeing a doctor may influence her/his hospital choice behavior through various ways. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The patient’s anxiety before seeing a doctor and her/his hospital choice behavior in China
  14. 1754
    “…We investigated the HER2 status in Korean breast cancer by immunohistochemistry (IHC) and silver-enhanced in situ hybridization (SISH), as the first step toward building a nationwide quality assurance program for HER2 testing. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer
  15. 1755
    “…It suppresses HER2 protein expression in a dose- and time-dependent manner. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κB
  16. 1756
    “…Gene amplification of EGFR and HER2 was observed in 7% (16/244) and 11% (27/245) of the ESCC specimens. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
  17. 1757
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
  18. 1758
    por Norton, Nadine, Perez, Edith A
    Publicado 2013
    “…Of the prognostic and predictive biological markers available, hormone receptors (defined as estrogen and progesterone receptors) and HER2 receptors, have been independently validated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?
  19. 1759
    “…BACKGROUND: Efficacious application of HER2-targetting agents requires the identification of novel predictive biomarkers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A gene expression profile indicative of early stage HER2 targeted therapy response
  20. 1760
    “…Specific cytolytic activity of retargeted T cells to kill HER2 positive SKBR3 cell line was evaluated in vitro. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
Herramientas de búsqueda: RSS